Navigation Links
Many of those living with HIV face a new life-threatening challenge: cancer
Date:6/6/2011

CHICAGO As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others. The alarming uptick in cancer rates highlights the critical need to understand how to treat tumors in people taking highly active anti-retroviral therapy (HAART) for HIV. Given what is known about HAART drug interactions, can newer targeted cancer therapies be given safely to patients with HIV?

To explore potential interactions between HAART and the newer cancer drugs, the AIDS Malignancy Consortium (AMC), a National Cancer Institute (NCI)-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers, has conducted the first of a planned series of studies. John Deeken, M.D., a research physician at Georgetown Lombardi Comprehensive Cancer Center and national chairman of the study, presented the findings today during a poster session at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

He says these early results already have the potential to change the way that cancer is treated in HIV patients.

"Up to this point, oncologists have not had much information about treating cancer in people taking HAART," says Deeken. "We're basically at square one because people with HIV usually are not included in cancer clinical trials. They're excluded because physicians are worried about causing further immune suppression in HIV patients, and because HAART drugs are notorious for causing drug-drug interactions and serious side effects."

The first drug being studied is sunitinib. Sunitinib (Sutent) may stop the growth of cancer cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. However, agents in the HAART cocktail are thought to affect the same enzymes involved in sunitinib metabolism.

The AMC chose to study sunitinib because this oral medication was approved by the Food and Drug Administration to treat kidney cancer, which is occurring at an increasing rate among HIV patients, and the drug is being studied in other cancer types that also affect HIV patients, such as lung and liver cancers.

Safety was examined separately for two groups within the phase I study. Group one included those whose HAART combination did not include ritonavir, while patients in group two were taking a ritonavir-based protease inhibitor HAART cocktail.

Between August 2009 and April 2011, a total of 19 patients were enrolled, treated, and completed at least one cycle of therapy. Sunitinib (50mg/day) was well tolerated in patients in group one those taking non-ritonavir based HAART regimens. Patients treated with sunitinib who were in group two, those taking the ritonavir-based therapy, experienced more side effects including higher rates of neutropenia (compared to those reported on phase III studies of sunitinib).

"Already, we have important information that can impact treatment," says Deeken. "When the trial is complete, we may have data to recommend that patients take different dosages of sunitinib based on what HAART cocktail they are taking. We also found that patients could keep taking their HIV medications safely, and that sunitinib did not affect the HIV disease status of patients in either group."

"Our HIV disease is now frequently being well controlled with HAART medications, but we are still having multiple medical problems including getting cancer earlier and more frequently," says James Weihe, a community representative for the AIDS Malignancy Consortium. "I am 60 years old and have been diagnosed with 3 minor cancers and 2 major cancers within the last 2 years. Frequently we are rejected from clinical trials just because we are HIV positive. Dr. Deeken and the work his colleagues are doing give us new hope. Their research shows that we can be included in cancer research trials if the dosages of the medications are adjusted to avoid drug-drug interactions and other side effects."

"The NCI has called for clinical trials criteria to include people with HIV though the adoption of these criteria has been slow," says Deeken. "Here we are, years after many new and effective anti-cancer treatments have been identified and we know so little about using these drugs in people who are also on therapy for their HIV. While the need for caution is understandable, it may be scientifically unjustified as well as fundamentally unfair to exclude patients with HIV from clinical trials."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Acupuncture of benefit to those with unexplained symptoms
2. Early Intervention Holds Hope for Those Who Stutter
3. Scientists Find Molecular Similarities in Brains of Those With Autism
4. Blood Pressure Drug Helps Those With Mild Heart Failure
5. Are All Those Handshakes at Graduation Hazardous to Your Health?
6. Can Platelet Transfusions Trigger Severe Reaction in Those With Peanut Allergies?
7. Study finds youth-mentor relationships particularly helpful for those experiencing hardship
8. Flood Cleanup Requires Extra Care for Those With Allergies
9. New mobile app gives a voice to those with communications challenges
10. Brains of Phonetics Experts Differ From Those of General Public
11. Apnea may be cause for awakening and voiding for those with enlarged prostates report Ben-Gurion U.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
Breaking Medicine Technology: